Mergers & Acquisitions

Mallinckrodt issued 13,170,932 new ordinary shares to its guaranteed unsecured noteholders.

The company’s North American cereal and plant-based food businesses will be spun off into two separate entities.

Pertuzumab is a treatment for certain patients with breast cancer, and denosumab is indicated for the treatment of certain patients with osteoporosis.

According to reports, Revlon is preparing to file for Chapter 11 within the next few days, following news that as of the end of March it had long-term debt of $3.31 billion.

Endo currently expects to launch the differentiated branded product in the United States in 2025.

Parata provides BD access to a new $600 million pharmacy automation market segment that is expected to grow approximately 10% annually to $1.5 billion in the United States alone over 10 years, according to the company.

The company is offering Lyvispah, a baclofen oral granules specialty product, and bexarotene gel, 1%.

The wholesale club retailer reached 6.5 million members in the first quarter, and membership fee income increased by 11.9% to $96.6 million year-over-year.